In short.
Once someone has successfully lost weight on an injection like Tirzepatide or semaglutide, two questions usually follow: do I have to keep injecting forever? and is there a pill that can take over? ATTAIN-MAINTAIN is about the second one.
376 adults who had previously taken part in SURMOUNT-5 — losing weight with Tirzepatide or semaglutide — were randomised in this follow-up trial: either switch to a daily orforglipron tablet, or switch to placebo. All received lifestyle support. A year later, most of the weight loss was preserved on orforglipron — while the placebo group regained a substantial portion.
What is orforglipron, exactly?
Orforglipron is a new molecule: a GLP-1 receptor agonist (similar mechanism to semaglutide), but in tablet form instead of an injection. An important distinction from other GLP-1 drugs: it's a non-peptide molecule, so it works orally without strict fasting rules.
Unlike Tirzepatide (which acts on two receptors: GLP-1 and GIP), orforglipron acts only on GLP-1. In trials so far, its efficacy and side-effect profile resemble semaglutide — not as potent as Tirzepatide for initial weight loss, but a serious player for maintenance.
Orforglipron is not (yet) approved in Europe. It cannot currently be prescribed in the Netherlands. Lunaris does not use it. This summary describes what is coming — not what we offer today.
What did they study?
The question was concrete: can a daily pill preserve the weight loss achieved with a weekly injection?
The researchers deliberately ran two parallel cohorts:
- Cohort 1 — 205 participants who had previously lost weight on Tirzepatide
- Cohort 2 — 171 participants who had previously lost weight on semaglutide
Within each cohort, participants were randomised to orforglipron or placebo. The orforglipron dose was titrated over 20 weeks, starting at 12 mg and going up to 36 mg per day (or the maximum tolerated dose). After 52 weeks, the change in weight from the start of this follow-up trial was measured.
What did they find?
Both cohorts showed a clear difference — orforglipron preserved a much larger share of weight loss than placebo:
— From Tirzepatide
74.7%
of the original weight loss preserved on orforglipron — versus 49.2% on placebo.
— From semaglutide
79.3%
of the original weight loss preserved on orforglipron — versus 37.6% on placebo.
Expressed in average weight terms:
~5 kg
Tirzepatide → orforglipron
On average 5 kg regained over 52 weeks — versus substantially more in the placebo group.
~1 kg
Semaglutide → orforglipron
Just 1 kg regained on average — near-complete preservation of the loss.
95.9 kg
Endpoint weight, both cohorts
Striking convergence — a possible biological set-point on orforglipron.
52 wk
Trial duration
One year of maintenance — brief for a chronic condition, but the first robust evidence.
Cardiometabolic gains — blood pressure, lipids, HbA1c, waist circumference — were largely preserved under orforglipron. In the placebo group, as weight returned, these markers also worsened.
What about side effects?
The side-effect profile was similar to other GLP-1 drugs. Mainly gastrointestinal during the early dose-escalation period: nausea (~13–23% vs 3–5% placebo), constipation (12–14% vs 3–5%), diarrhoea (~7%) and vomiting (~5–11%). Most complaints were mild to moderate and subsided after a few weeks.
Serious adverse events were rare (1–2% in each arm). One death was reported in cohort 2 (orforglipron group) from a cardiovascular cause; the independent committee did not attribute it to the trial drug. Two confirmed cases of mild pancreatitis (one per cohort) in the orforglipron group — a known, rare side effect of the GLP-1 class. No liver toxicity, no thyroid cancer.
What does this mean for you?
For now, mostly perspective — no direct change to what Lunaris can offer today. But an important development to track:
- In the Netherlands today: orforglipron is not yet available here. For maintenance after a Tirzepatide programme, we look at continuing on a lower dose of Tirzepatide (see the SURMOUNT-MAINTAIN summary) or carefully tapering with lifestyle as the foundation.
- In the coming years: if orforglipron is approved in Europe, it could become a valuable addition — especially for patients who dislike injections, or who'd prefer a simpler medication during the maintenance phase.
- Maintenance still matters: the trial confirms once again that obesity is a chronic condition. Doing nothing during the maintenance phase leads to regain — just like with other chronic conditions.
We follow the European approval process around orforglipron closely. As soon as it becomes available in the Netherlands and is incorporated into guidelines, we will assess whether and how we can responsibly offer it.
Important caveats.
— No direct injection-vs-pill comparison
The trial compares orforglipron to placebo, not to a lower-dose injection. So we don't yet know whether the pill is better, worse, or equivalent to, say, 5 mg maintenance Tirzepatide. Future research must make that head-to-head comparison.
— Only one year
The trial lasted one year. Whether orforglipron still preserves outcomes after 3–5 years is unknown.
— Mostly people without diabetes
People with type 2 diabetes were excluded. For those with both obesity and diabetes, the calculus may differ, and future research will need to clarify.
— Funded by Eli Lilly
Eli Lilly manufactures both Tirzepatide and orforglipron — and funded this trial. The data are peer-reviewed in Nature Medicine, but it's worth being aware of the commercial stake.
— Many placebo participants stopped or were rescued
In cohort 2, only 18% of the placebo group completed the entire trial without any other intervention. The "true" effect of fully stopping may therefore be even less favourable than the figures in this paper suggest.
— Original source
Aronne LJ, Jastreboff AM, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature Medicine, 2026.
DOI: 10.1038/s41591-026-04386-7 · ClinicalTrials.gov: NCT06584916 · Full publication subscriber-only; abstract openly available.
Read the full article →